Aigen Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Aigen Investment Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,614	Closed	-$450K	–	551
2026 Q1	$450K	Buy	+1,614	New	+$465K	0.12%	238
2024 Q3	–	Sell	-2,427	Closed	-$663K	–	744
2024 Q2	$663K	Buy	2,427 +1,752	+260%	+$510K	0.13%	226
2024 Q1	$233K	Sell	675 -454	-40%	-$149K	0.05%	508
2023 Q4	$365K	Buy	+1,129	New	+$354K	0.07%	431
2023 Q1	–	Sell	-2,719	Closed	-$1.14M	–	623
2022 Q4	$1.14M	Buy	2,719 +2,006	+281%	+$810K	0.16%	156
2022 Q3	$297K	Buy	713 +237	+50%	+$118K	0.04%	402
2022 Q2	$236K	Buy	+476	New	+$248K	0.04%	432

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Aigen Investment Management's BIO Position: Q2 2026 in Review

Aigen Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 1,614 shares — an estimated $450K sold.

Aigen Investment Management first reported a position in BIO in Q2 2022 and held it in 7 quarters. The position peaked at $1.14M in Q4 2022. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Aigen Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
Aigen Investment Management sold 1,614 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $450K.
Aigen Investment Management first reported a position in Bio-Rad Laboratories Class A in Q2 2022 and held it in 7 quarters.
Aigen Investment Management's Bio-Rad Laboratories Class A position peaked at $1.14M in Q4 2022.
400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.